US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
AU519567B2
(en)
|
1977-07-13 |
1981-12-10 |
Akzo Nv |
Psychopharmacological penta and hexa-peptides
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
US4601903A
(en)
|
1985-05-01 |
1986-07-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
US6024983A
(en)
|
1986-10-24 |
2000-02-15 |
Southern Research Institute |
Composition for delivering bioactive agents for immune response and its preparation
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US4849222A
(en)
|
1987-03-24 |
1989-07-18 |
The Procter & Gamble Company |
Mixtures for treating hypercholesterolemia
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
JP2670680B2
(ja)
|
1988-02-24 |
1997-10-29 |
株式会社ビーエムジー |
生理活性物質含有ポリ乳酸系微小球およびその製造法
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
EP0739904A1
(de)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispezifische Reagenzien für die AIDS-Therapie
|
WO1991003489A1
(en)
|
1989-09-08 |
1991-03-21 |
The Johns Hopkins University |
Structural alterations of the egf receptor gene in human gliomas
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
WO1992000373A1
(en)
|
1990-06-29 |
1992-01-09 |
Biosource Genetics Corporation |
Melanin production by transformed microorganisms
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1992019971A1
(en)
|
1991-04-30 |
1992-11-12 |
Alkermes, Inc. |
Cationized antibodies against intracellular proteins
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
WO1993006213A1
(en)
|
1991-09-23 |
1993-04-01 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
US5288502A
(en)
|
1991-10-16 |
1994-02-22 |
The University Of Texas System |
Preparation and uses of multi-phase microspheres
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
CA2129663C
(en)
|
1992-02-06 |
2005-07-05 |
James S. Huston |
Biosynthetic binding protein for cancer marker
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
DE69334095T2
(de)
|
1992-07-17 |
2007-04-12 |
Dana-Farber Cancer Institute, Boston |
Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
|
EP0652775B1
(de)
|
1992-07-27 |
2000-04-19 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Zielgerichte liposome zur blut-hirne schranke
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
NZ258392A
(en)
|
1992-11-13 |
1997-09-22 |
Idec Pharma Corp |
Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
|
CA2172509C
(en)
|
1993-10-22 |
2010-08-24 |
Jeffrey L. Cleland |
Methods and compositions for microencapsulation of antigens for use as vaccines
|
US6544952B1
(en)
|
1994-03-15 |
2003-04-08 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of glycoconjugates of the globo-H epitope and uses thereof
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
WO1996030347A1
(en)
|
1995-03-30 |
1996-10-03 |
Pfizer Inc. |
Quinazoline derivatives
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
KR20050085971A
(ko)
|
1995-04-27 |
2005-08-29 |
아브게닉스, 인크. |
면역화된 제노마우스 유래의 인간 항체
|
AU2466895A
(en)
|
1995-04-28 |
1996-11-18 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
EP0831880A4
(de)
|
1995-06-07 |
2004-12-01 |
Imclone Systems Inc |
Antikörper und deren fragmente zur hemmung von tumorwachstum
|
AU2660397A
(en)
|
1996-04-05 |
1997-10-29 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
EP0892789B2
(de)
|
1996-04-12 |
2009-11-18 |
Warner-Lambert Company LLC |
Umkehrbare inhibitoren von tyrosin kinasen
|
US6231859B1
(en)
|
1996-12-02 |
2001-05-15 |
Aquila Biopharmaceuticals, Inc. |
Saponin adjuvant compositions
|
EP2314625B1
(de)
|
1996-12-03 |
2014-05-07 |
Amgen Fremont Inc. |
Transgene Säugetiere, die menschliche Ig-loci einschliesslich mehrere VH und Vkappa Regionen enthalten, und davon erhaltene Antikörper
|
AUPO517897A0
(en)
|
1997-02-19 |
1997-04-11 |
Csl Limited |
Chelating immunostimulating complexes
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
US7018637B2
(en)
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
AUPP807399A0
(en)
|
1999-01-08 |
1999-02-04 |
Csl Limited |
Improved immunogenic lhrh composition and methods relating thereto
|
NZ513935A
(en)
|
1999-02-17 |
2004-02-27 |
Csl Ltd |
Immunogenic complexes and methods relating thereto
|
WO2000049412A1
(en)
|
1999-02-17 |
2000-08-24 |
Glycominds Ltd. |
Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
|
US7824687B2
(en)
|
1999-08-20 |
2010-11-02 |
Sloan-Kettering Institute For Cancer Research |
Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
|
US7854934B2
(en)
|
1999-08-20 |
2010-12-21 |
Sloan-Kettering Institute For Cancer Research |
Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
|
US6514221B2
(en)
|
2000-07-27 |
2003-02-04 |
Brigham And Women's Hospital, Inc. |
Blood-brain barrier opening
|
US20020065259A1
(en)
|
2000-08-30 |
2002-05-30 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
US7034036B2
(en)
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
US20030083299A1
(en)
|
2000-11-04 |
2003-05-01 |
Ferguson Ian A. |
Non-invasive delivery of polypeptides through the blood-brain barrier
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
WO2002086096A2
(en)
|
2001-01-23 |
2002-10-31 |
University Of Rochester Medical Center |
Methods of producing or identifying intrabodies in eukaryotic cells
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
EP2147679B1
(de)
|
2001-07-25 |
2014-06-25 |
Raptor Pharmaceutical, Inc. |
Zusammensetzungen für den Blut-Hirn-Schrankentransport
|
WO2003015796A1
(en)
|
2001-08-14 |
2003-02-27 |
Biomira, Inc. |
Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier
|
EP1482972A4
(de)
|
2001-11-20 |
2005-11-23 |
Seattle Genetics Inc |
Behandlung von immunologischen störungen unter verwendung von anti-cd30 antikörpern
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
AU2003219277A1
(en)
|
2002-03-14 |
2003-09-29 |
Medical Research Council |
Intracellular antibodies
|
CA2494104A1
(en)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
EP1391213A1
(de)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Zusammensetzungen und Verfahren zur Behandlung von Krebs mit einem Maytansinoid-CD44-Antikörper Immunokonjugat und chemotherapeutische Mittel
|
AU2003287345A1
(en)
|
2002-10-31 |
2004-06-07 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
KR101111477B1
(ko)
|
2002-12-03 |
2012-02-23 |
블랜체트 록펠러 뉴로사이언시즈 인스티튜트 |
치료제와 연결된 콜레스테롤을 포함하는 접합체
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
US20060035267A1
(en)
|
2003-04-09 |
2006-02-16 |
Livingston Philip O |
Optimal polyvalent vaccine for cancer
|
GB0316294D0
(en)
|
2003-07-11 |
2003-08-13 |
Polytherics Ltd |
Conjugated biological molecules and their preparation
|
ATE475430T1
(de)
|
2003-08-25 |
2010-08-15 |
Univax Llc |
Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls
|
JP2007505142A
(ja)
|
2003-09-10 |
2007-03-08 |
セダーズ−シナイ メディカル センター |
血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
|
EP1723422A2
(de)
|
2004-03-05 |
2006-11-22 |
The Scripps Research Institute |
Glycan-mikroarray mit hohem durchsatz
|
EP2484374A1
(de)
|
2004-07-18 |
2012-08-08 |
CSL Limited |
Immunstimulierender Komplex und Oligonucleotidformulierungen zur Induzierung verbesserter Interferon-Gamma-Antworten
|
WO2006134423A2
(en)
|
2004-07-18 |
2006-12-21 |
Coley Pharmaceutical Group, Ltd. |
Methods and compositions for inducing innate immune responses
|
CN103361300B
(zh)
|
2005-03-31 |
2015-04-01 |
斯丹姆涅恩有限公司 |
用高度纯化来自羊膜的细胞群制备的条件培养基
|
JP5129143B2
(ja)
|
2005-10-07 |
2013-01-23 |
エグゼリクシス, インコーポレイテッド |
Mekインヒビターおよびその使用方法
|
EP1951281B1
(de)
|
2005-10-17 |
2015-04-15 |
Sloan Kettering Institute For Cancer Research |
Wt1 hla klasse ii-bindungspeptide und diese umfassende zusammensetzungen und verfahren
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
WO2009035494A2
(en)
|
2007-07-30 |
2009-03-19 |
The Scripps Research Institute |
Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
|
JPWO2009044918A1
(ja)
|
2007-10-05 |
2011-02-17 |
武田薬品工業株式会社 |
ニューロメジンu誘導体
|
US20110117009A1
(en)
|
2008-03-31 |
2011-05-19 |
Freie Universität Berlin |
Drug conjugates with polyglycerols
|
KR101825315B1
(ko)
|
2008-04-08 |
2018-02-02 |
슬로안-케테링인스티튜트퍼캔서리서치 |
트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
|
AU2009268937A1
(en)
*
|
2008-06-16 |
2010-01-14 |
Aj Park |
Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
|
CN102137892A
(zh)
|
2008-08-29 |
2011-07-27 |
阿克佐诺贝尔股份有限公司 |
阻燃剂聚烯烃组合物
|
CN105535955B
(zh)
|
2009-06-16 |
2019-04-23 |
中央研究院 |
Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
|
EP2347769A1
(de)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Krebsstammzellenmarker und Verwendungen damit
|
WO2011156774A2
(en)
|
2010-06-11 |
2011-12-15 |
Sloan-Kettering Institute For Cancer Research |
Multivalent glycopeptide constructs and uses thereof
|
US9175326B2
(en)
|
2011-03-03 |
2015-11-03 |
University Of Maryland, Baltimore |
Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae
|
EP2500035A1
(de)
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmazeutische Formulierung mit Immunglobulin
|
EP3228325A1
(de)
|
2011-06-10 |
2017-10-11 |
Mersana Therapeutics, Inc. |
Protein-polymer-wirkstoffkonjugate
|
CA2862925C
(en)
|
2012-02-10 |
2020-01-21 |
University Of Maryland, Baltimore |
Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
|
WO2013126746A2
(en)
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
EP2825156B1
(de)
|
2012-03-16 |
2017-07-26 |
Merck Patent GmbH |
Targeting mit aminosäure-lipiden
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP2941436B1
(de)
|
2013-01-04 |
2020-12-02 |
OBI Pharma, Inc. |
Impfstoffe mit erhöhter kohlenhydrat-antigen-dichte und einem neuartigen saponin-adjuvans
|
US10307471B2
(en)
|
2013-05-02 |
2019-06-04 |
National Institute Of Advanced Industrial Science And Technology |
Immunity inducer for saccharide antigens
|
WO2015159118A2
(en)
|
2013-09-17 |
2015-10-22 |
Obi Pharma, Inc. |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP2017507118A
(ja)
|
2014-01-16 |
2017-03-16 |
アカデミア シニカAcademia Sinica |
がんの処置および検出のための組成物および方法
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
CN106456766B
(zh)
|
2014-03-19 |
2020-03-10 |
台湾基督长老教会马偕医疗财团法人马偕纪念医院 |
抗免疫原性糖肽的抗体、包含其的组合物及其用途
|
ES2693035T3
(es)
|
2014-04-01 |
2018-12-07 |
Miltenyi Biotec Gmbh |
SSEA4 y ST3GAL2 como biomarcadores de respuesta a fármacos quimioterapéuticos
|
TWI609886B
(zh)
|
2014-04-10 |
2018-01-01 |
台灣浩鼎生技股份有限公司 |
抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
JP6588084B2
(ja)
|
2014-08-19 |
2019-10-09 |
ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ssea4抗原に特異的なキメラ抗原受容体
|
CA2961522A1
(en)
*
|
2014-09-15 |
2016-03-24 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycoconjugate compositions and uses thereof
|
EP3248013B1
(de)
|
2015-01-24 |
2020-07-15 |
Academia Sinica |
Krebsmarker und verfahren zur verwendung davon
|
CN107614521B
(zh)
|
2015-01-30 |
2022-02-08 |
台湾地区“中央研究院” |
增进抗体功效的通用糖型组合物及方法
|
MA42272A
(fr)
|
2015-06-29 |
2018-05-02 |
Univ Johns Hopkins |
Thérapie faisant intervenir des récepteurs antigéniques chimériques de point de contrôle immunitaire
|
TWI730972B
(zh)
|
2015-07-16 |
2021-06-21 |
日商第一三共股份有限公司 |
新穎EndoS變異酵素及使用其之經糖鏈重塑之含Fc區域的分子之製造方法
|
JP2018532990A
(ja)
|
2015-09-04 |
2018-11-08 |
オービーアイ ファーマ,インコーポレイテッド |
グリカンアレイおよび使用の方法
|
JP2018536628A
(ja)
|
2015-10-07 |
2018-12-13 |
オービーアイ ファーマ インコーポレイテッド |
新規炭水化物抗体、医薬組成物およびその使用
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3445395A4
(de)
|
2016-04-22 |
2019-12-25 |
OBI Pharma, Inc. |
Krebsimmuntherapie mittels immunaktivierung oder immunmodulation über antigene der globo-reihe
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
BR112019010356A2
(pt)
|
2016-11-21 |
2019-08-27 |
Obi Pharma Inc |
molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
|